1296835-86-3

Upstream product

• 108-95-2 phenol 
• 6968-35-0 7-hydroxy-indan-1-one 
• 2746-25-0 p-Methoxybenzyl bromide 

Downstream Products

• 1296835-87-4 9-(4-methoxy-benzyloxy)-4-phenyl-5H-indeno[1,2-d]pyrimidin-2-ylamine 
• 1296835-47-6 9-[4-(4-Acetyl-phenyl)-piperazin-1-yl]-2-amino-4-phenyl-indeno[1,2-d]pyrimidin-5-one 
• 1296835-89-6 2-amino-9-(4-methoxy-benzyloxy)-4-phenyl-indeno[1,2-d]pyrimidin-5-one 
• 1296835-91-0 2-amino-9-hydroxy-4-phenyl-indeno[1,2-d]pyrimidin-5-one 
• 1296835-93-2 trifluoro-methanesulfonic acid 2-amino-5-oxo-4-phenyl-5H-indeno[1,2-d]pyrimidin-9-yl ester 
• 1297597-30-8 2-amino-9-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-4-phenyl-indeno[1,2-d]pyrimidin-5-one 
• 69676-26-2 2-benzylidene-7-hydroxy-2,3-dihydro-1H-inden-1-one 

Relevant academic research and scientific papers

Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors

A novel series of 2-benzyl-1-indanone analogs were investigated as IL-5 inhibitory activity. Among the synthesized compounds, 7-(cyclohexylmethoxy)-2-(4-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7s, 100.0% inhibition at 30 μM, IC50 = 4.0 μM), and 7-(cyclohexylmethoxy)-2-(3-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7t, 95.0% inhibition at 30 μM, IC50 = 6.0 μM) showed the best inhibitory activity against IL-5. The 2-benzyl-1-indanone analogs showed moderate to strong IL-5 inhibitory activity. Especially, hydroxyl (HBD/HBA) substituent at position 3 or 4 on phenyl ring B showed potent IL-5 inhibition. Additionally, the bulky hydrophobic cyclohexylmethoxy group at position 7 of the 1-indanone ring is favorable for the inhibitory activity.

HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS

This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are as defined in the specification.

HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS

This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are as defined in the specification.

2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST

This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease.